What term describes the accelerated IND process for urgent health threats?

• A. Expedited Approval
• B. Treatment INDs
• C. Orphan Drugs
• D. Benoxaprofen

Answer: (A)

The concept being tested is speeding up regulatory pathways to get potentially lifesaving therapies to patients during urgent health threats. Expedited Approval describes a mechanism that allows the FDA to review and approve drugs more quickly for serious or life-threatening conditions, often based on early or surrogate data with the requirement of confirmatory studies after approval. This approach balances rapid access with ongoing safety and effectiveness monitoring, which is why it fits as the term for an accelerated IND-related process aimed at urgent needs.

Treatment INDs are about providing access to investigational drugs for patients with no good options while a trial is ongoing, but they are not the overarching expedited pathway used to accelerate the IND process for urgent threats. Orphan Drugs refer to therapies for rare diseases with special incentives, and Benoxaprofen is a specific drug name that is unrelated to the regulatory term in question.